http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2329076-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2006-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04fbeb5209c87649b889e1020c794317 |
| publicationDate | 2009-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2329076-T3 |
| titleOfInvention | DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASES RECEIVING EGF AND / OR ERBB2. |
| abstract | A quinazoline derivative of Formula I: ** see formula ** in which: R1 is selected from hydrogen, hydroxy, (C1-4) alkoxy and (C1-4) alkoxy (C1-4) alkoxy; each of G1, G2, G3, G4 and G5 is independently selected from hydrogen and halogen; X1 is selected from SO2, CO, SO2N (R7) and C (R7) 2, where each R7 is independently selected from hydrogen and (C1-4) alkyl; Q1 is aryl or heteroaryl, where the aryl or heteroaryl group optionally has one or more substituents independently selected from halogen, cyano and (C1-4) alkoxy; each of R2, R3, R4 and R5 is independently selected from hydrogen and (C1-4) alkyl, or R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl ring, or R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl ring. R6 is selected from hydrogen and (C1-4) alkyl; A is selected from hydrogen, a group of the formula Z- (CR8R9) p- and R10, where p is 1, 2, 3 or 4, each of R8 and R9 is independently selected from hydrogen and (C1-) alkyl 4), or an R8 group and an R9 group attached to the same carbon atom form a cyclopropyl ring, Z is selected from hydrogen, OR11 and NR12R13, where each of R11, R12 and R13 is independently selected from hydrogen and alkyl (C1-4), and R10 is selected from (C1-4) alkoxy and NR12R13, where R12 and R13 are as defined above, and where any CH2 or CH3 group within a Z group or an R10 group optionally has each of said CH2 or CH3 groups one or more substituents independently selected from halogen, (C1-4) alkyl, hydroxy and (C1-4) alkoxy; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2005-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 850.